Cargando…
Do adrenergic alpha‐antagonists increase the risk of poor cardiovascular outcomes? A systematic review and meta‐analysis
Due to concerns regarding neurohormonal activation and fluid retention, adrenergic alpha‐1 receptor antagonists (A1Bs) are generally avoided in the setting of heart disease, namely, symptomatic heart failure (HF) with reduced ejection fraction (HFrEF). However, this contraindication is mainly suppor...
Autores principales: | Sousa, José Pedro, Mendonça, Diogo, Teixeira, Rogério, Gonçalves, Lino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715777/ https://www.ncbi.nlm.nih.gov/pubmed/35894772 http://dx.doi.org/10.1002/ehf2.14012 |
Ejemplares similares
-
Meta-analysis of the efficacy and adverse drug reactions of adrenergic alpha-antagonists in treating children with ureteral calculi
por: Sun, Kai, et al.
Publicado: (2023) -
The Alpha-1 Adrenergic Receptor Antagonist Prazosin Reduces Binge-Like Eating in Rats
por: Hicks, Callum, et al.
Publicado: (2020) -
The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19
por: Rose, Liam, et al.
Publicado: (2021) -
The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19
por: Rose, Liam, et al.
Publicado: (2021) -
Beta adrenergic antagonists and antianginal drugs
por: Stever, Lindsey M., et al.
Publicado: (2021)